DL-Pro-NHi-Pr

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-Pro-NHi-Pr
• 英文别名: N-Isopropylpyrrolidine-2-carboxamide；N-propan-2-ylpyrrolidine-2-carboxamide
• 化学式: C₈H₁₆N₂O
• 分子量: 156.228
• InChiKey: AUACPLOGXSJUHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  DL-Pro-NHi-Pr 以 二氯甲烷 为溶剂， 反应 0.46h， 生成 Piv-L-Pro-NHi-Pr
  参考文献：
  名称：

  Hosten, N.; Antenuis, M.J.O, Bulletin des Societes Chimiques Belges, 1988, vol. 97, # 1, p. 48 - 50

  摘要：

  DOI：
• 作为产物：
  描述：

  四氢-1H,3H-吡咯并[1,2-c]恶唑-1,3-二酮 、 异丙胺 以 二氯甲烷 为溶剂， 生成 DL-Pro-NHi-Pr
  参考文献：
  名称：

  Hosten, N.; Antenuis, M.J.O, Bulletin des Societes Chimiques Belges, 1988, vol. 97, # 1, p. 48 - 50

  摘要：

  DOI：

文献信息

• CATALYST FOR ASYMMETRIC HYDROGENATION
  申请人：MAEDA Hironori

  公开号：US20100324338A1

  公开（公告）日：2010-12-23

  This invention aims at providing a catalyst for producing an optically active aldehyde or an optically active ketone, which is an optically active carbonyl compound, by carrying out selective asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, particularly a catalyst which is insoluble in a reaction mixture for obtaining optically active citronellal which is useful as a flavor or fragrance, by carrying out selective asymmetric hydrogenation of citral, geranial or neral; and a method for producing a corresponding optically active carbonyl compound. The invention relates to a catalyst for asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, which comprises a powder of at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table, or a metal-supported substance in which at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table is supported on a support, an optically active cyclic nitrogen-containing compound and an acid.

  这项发明旨在通过对α，β-不饱和羰基化合物进行选择性不对称加氢，特别是通过对柠檬醛、香叶醛或柠檬醛进行选择性不对称加氢，从而提供用作香料或香精的有用的光学活性香茅醛的催化剂，该香茅醛是一种光学活性羰基化合物；以及生产相应的光学活性羰基化合物的方法。该发明涉及一种用于不对称加氢α，β-不饱和羰基化合物的催化剂，其包括来自周期表第8至第10族金属中至少一种金属的粉末，或者至少一种来自周期表第8至第10族金属的金属负载物质，该金属负载在一种支撑物上，还包括光学活性的含氮环化合物和酸。
• Dolastatin 15 derivatives
  申请人：Janssen Bernd

  公开号：US20060270606A1

  公开（公告）日：2006-11-30

  Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G) r -(K) s -L   (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

  本发明的化合物包括细胞生长抑制剂，其为式I中的肽，A-B-D-E-F-(G)r-(K)s-L，以及其酸盐，其中A、B、D、E、F、G和K是α-氨基酸残基，s和r各自独立地为0或1。L是单价基团，例如氨基、N-取代氨基、β-羟胺基、肼基、烷氧基、硫烷氧基、氨氧基或氧化肟基。本发明还包括一种用于治疗哺乳动物（例如人类）癌症的方法，包括向哺乳动物中给予式I化合物的有效量，以一种药学上可接受的组合物形式。
• DOLASTATIN 15 DERIVATIVES
  申请人：JANSSEN Bernd

  公开号：US20100099843A1

  公开（公告）日：2010-04-22

  Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G) r -(K) s -L  (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

  本发明的化合物包括细胞生长抑制剂，其为公式I中的肽，A-B-D-E-F-(G)r-(K)s-L（I），以及其酸盐，其中A、B、D、E、F、G和K均为α-氨基酸残基，s和r各自独立地为0或1。L是单价基团，例如氨基、N-取代氨基、β-羟胺基、肼基、烷氧基、硫烷氧基、氨氧基或氧肟基等。本发明还包括一种治疗哺乳动物（例如人类）癌症的方法，包括向哺乳动物中以药学上可接受的组成物的有效量给予公式I的化合物。
• COMPOUNDS USEFUL FOR INHIBITING CHK1
  申请人：Keegan Kathleen S.

  公开号：US20100105683A1

  公开（公告）日：2010-04-29

  Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.

  本发明公开了用于治疗与DNA损伤或DNA复制中的损伤有关的疾病和病症的芳基和杂环基取代脲化合物。本发明还公开了制备该化合物的方法以及它们作为治疗剂的用途，例如，在治疗癌症和其他以DNA复制缺陷、染色体分离或细胞分裂为特征的疾病中。
• DOLASTATIN PENTAPEPTIDE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP0915908A1

  公开（公告）日：1999-05-19